Your browser doesn't support javascript.
loading
An effective drug-disease associations prediction model based on graphic representation learning over multi-biomolecular network.
Jiang, Hanjing; Huang, Yabing.
Afiliação
  • Jiang H; Key Laboratory of Image Information Processing and Intelligent Control of Education Ministry of China, Institute of Artificial Intelligence, School of Artificial Intelligence and Automation, Huazhong University of Science and Technology, Wuhan, 430074, China.
  • Huang Y; Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China. ybhuangwhu@163.com.
BMC Bioinformatics ; 23(1): 9, 2022 Jan 04.
Article em En | MEDLINE | ID: mdl-34983364
ABSTRACT

BACKGROUND:

Drug-disease associations (DDAs) can provide important information for exploring the potential efficacy of drugs. However, up to now, there are still few DDAs verified by experiments. Previous evidence indicates that the combination of information would be conducive to the discovery of new DDAs. How to integrate different biological data sources and identify the most effective drugs for a certain disease based on drug-disease coupled mechanisms is still a challenging problem.

RESULTS:

In this paper, we proposed a novel computation model for DDA predictions based on graph representation learning over multi-biomolecular network (GRLMN). More specifically, we firstly constructed a large-scale molecular association network (MAN) by integrating the associations among drugs, diseases, proteins, miRNAs, and lncRNAs. Then, a graph embedding model was used to learn vector representations for all drugs and diseases in MAN. Finally, the combined features were fed to a random forest (RF) model to predict new DDAs. The proposed model was evaluated on the SCMFDD-S data set using five-fold cross-validation. Experiment results showed that GRLMN model was very accurate with the area under the ROC curve (AUC) of 87.9%, which outperformed all previous works in terms of both accuracy and AUC in benchmark dataset. To further verify the high performance of GRLMN, we carried out two case studies for two common diseases. As a result, in the ranking of drugs that were predicted to be related to certain diseases (such as kidney disease and fever), 15 of the top 20 drugs have been experimentally confirmed.

CONCLUSIONS:

The experimental results show that our model has good performance in the prediction of DDA. GRLMN is an effective prioritization tool for screening the reliable DDAs for follow-up studies concerning their participation in drug reposition.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / MicroRNAs / RNA Longo não Codificante Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Bioinformatics Assunto da revista: INFORMATICA MEDICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / MicroRNAs / RNA Longo não Codificante Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Bioinformatics Assunto da revista: INFORMATICA MEDICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China